QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Neoadjuvant Therapy for Locally Advanced or Oligometastatic Prostate Cancer: a Retrospective Comparative Single-Center Study 期刊论文 INDIAN JOURNAL OF SURGERY, 2022 作者:  Wang, Qibo;  Xu, Yipeng;  Zeng, Xiaowei;  Chen, Jinchao;  He, Yedie 收藏  |  浏览/下载：26/0  |  提交时间：2022/05/16 Prostate cancer  Neoadjuvant chemohormonal therapy  Neoadjuvant hormonal therapy  Prostatectomy  Surgical outcomes   A Novel Prognostic Factor TIPE2 in Bladder Cancer 期刊论文 PATHOLOGY & ONCOLOGY RESEARCH, 2022, 卷号: 28 作者:  Jiang, Yu;  Zhang, Zhiqiang;  Wang, Xian;  Feng, Zhenzhong;  Hong, Bo 收藏  |  浏览/下载：23/0  |  提交时间：2022/05/16 epithelial-mesenchymal transition  bladder cancer  TIPE2  cystectomy  urothelial carcinoma   Clinical Relevance of PD-L1 Expression and CD8+T Cells' Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma 期刊论文 FRONTIERS IN ONCOLOGY, 2021, 卷号: 11 作者:  Xu, Xiaoling;  Li, Na;  Wang, Ding;  Chen, Wei;  Fan, Yun 收藏  |  浏览/下载：39/0  |  提交时间：2021/08/31 invasive mucinous adenocarcinoma  lung cancer  PD-L1 expression  CD8+T cells  tumor microenvironment  genetic characteristics  treatment   High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer 期刊论文 TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10 作者:  Tong, Ying-Hui;  Hu, Xiao-Ping;  Xiang, Xue-Ping;  Fang, Luo 收藏  |  浏览/下载：66/0  |  提交时间：2021/05/17 Monocarboxylate transporter 1 (MCT1)  monocarboxylate transporter 4 (MCT4)  prognosis  non-small cell lung cancer (NSCLC)   PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy 期刊论文 LUNG CANCER, 2020, 卷号: 142 作者:  Chen, Kaiyan;  Cheng, Guoping;  Zhang, Fanrong;  Zhu, Guanxia;  Xu, Yanjun 收藏  |  浏览/下载：27/0  |  提交时间：2020/11/26 Uncommon EGFR  Non-small cell lung cancer  PD-L1  T cell  Immunotherapy